# Proviva Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/proviva-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Total disclosed funding: $18M
- Latest round: Series A (Dec 1, 2025)
- Investors on record: 6

## About

Founded in 2019 and based in Shanghai, China, Boshi Biotechnology (Shanghai) Co., Ltd., trading under the name Proviva Therapeutics, develops cytokine-based antitumor biologics using proprietary prodrug and immune-activation platforms. The company focuses on oncology indications and provides early-stage and clinical biologic candidates, including PTX-912. It operates as a subsidiary of Viva Biotech Holdings and conducts research targeting both tumor and infectious-disease applications. In December 2025, the firm closed a series A+ funding round led by OrbiMed Advisors.

The company works with pharmaceutical partners and research organizations to develop cytokine-based antitumor biologics, including the Crossover cytokine prodrug platform, the MUSICA immune-cell activation platform and candidates such as PTX-912.

The company’s revenue is generated through research partnerships, licensing agreements and collaboration arrangements with pharmaceutical companies. 

The company plans to advance global clinical development of PTX-912, expand its preclinical biologic pipeline and continue developing cytokine-focused platforms for oncology applications.

## Funding rounds

- Series A, Dec 1, 2025 — OrbiMed Advisors, HSG, Hankang Capital
- Series A, Mar 5, 2024, $18M — Lapam Capital, Sangel Capital, Ennovation Ventures

## Investors

- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series A
- Sangel Capital (https://capitalatlas.ai/funds/sangel-capital) — Series A
- Ennovation Ventures (https://capitalatlas.ai/funds/ennovation-ventures) — Series A
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- HSG (https://capitalatlas.ai/funds/hsg) — Series A
- Hankang Capital (https://capitalatlas.ai/funds/hankang-capital) — Series A